|Bid||3.0700 x 1800|
|Ask||3.0700 x 1100|
|Day's Range||2.7400 - 3.0800|
|52 Week Range||1.8200 - 5.1900|
|Beta (5Y Monthly)||2.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China.
Image source: The Motley Fool. GlycoMimetics Inc (NASDAQ: GLYC)Q4 2020 Earnings CallMar 2, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and thank you all for joining the GlycoMimetics call.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million.